← Oncology Approval Tracker

FDA DECISION ·

Kisqali / Kisqali Femara Co-Pack

ribociclib with an aromatase inhibitor; ribociclib and letrozole co-pack · Novartis

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant use of ribociclib with an aromatase inhibitor, including the ribociclib and letrozole co-pack, for adults with HR-positive, HER2-negative stage II or III early breast cancer at high risk of recurrence.

LAMPGEN ANALYSIS

Why it matters

Ribociclib entered the adjuvant setting for a defined high-risk population; the early-stage dose and course differ from metastatic use.

What research teams should watch

Verify stage and recurrence risk in the record, then plan long-term adherence checks, ECGs and blood tests.

PRIMARY RECORDS

Sources